Amrutanjan Health Care Limited · NSE:AMRUTANJAN
Amrutanjan Health Care — Q3 FY23 Earnings Presentation
18 slides from Amrutanjan Health Care's earnings presentation, Feb 14, 2023
Slide 1: Stock exchange cover letter for investor presentation
AHCL/ SE/ 46/2022-23 February 14, 2023 The National Stock Exchange of India Limited BSE Limited "Exchange Plaza", C-1, Block G Department of Corporate Services Bandra-Kurla Complex, Bandra (E) 1st Floor, Mumbai 400 051 P.J. Towers, Dalal Street, !SIN: INE098F01031 Mumbai 400 001 Symbol : AM RUTANJAN
Slide 2: Amrutanjan Health Care Limited Investor Presentation
Amrutanjan Health Care Limited Investor Presentation - Quarter & Period Ended 31st December 2022 Date: 14th February 2023
Slide 3: Contents
Contents a. Business Update b. YTD Dec’22 Performance c. Q3 FY23 Performance d. Way Forward Investor Presentation | Quarter and Period Ended 31st December 2022 2
Slide 4: Business Update
Business Update Investor Presentation | Quarter and Period Ended 31st December 2022 3
Slide 5: Business Update
Business Update A. We continue to see slowdown in the pain category even in the Q3 (source: IQVIA report) B. Inspite of these challenging times, a deep dive of the business (story behind numbers) shows a. Comfy has grown by 16% b. Growth in body pain products c. Head roll growing at double digit d.
Slide 6: Amrutanjan Period Pain Relief Roll-on
Business Update Amrutanjan Period Pain Relief Roll-on W NE U C T R OD P Investor Presentation | Quarter and Period Ended 31st December 2022 5
Slide 7: YTD Dec'22 Performance
YTD Dec’22 Performance Investor Presentation | Quarter and Period Ended 31st December 2022 6
Slide 8: Financials – YTD Dec'22
Financials – YTD Dec’22 (Rs. in Crores) Gross Sales Profit Before Tax Profit After Tax 331.48 310.42 52.48 70.56 37.17 27.14 YTD Dec'22 YTD Dec'21 YTD Dec'22 YTD Dec'21 YTD Dec'22 YTD Dec'21 Investor Presentation | Quarter and Period Ended 31st December 2022 7
Slide 9: Major reasons for reduction in Profit Before Tax
Financials – YTD Dec’22 (Rs. in Crores) Major reasons for reduction in Profit Before Tax (YTD Dec’22 vs YTD Dec’21): Particulars Amount Remarks Top Line reduction: Key Product 8 ML balm sales has come down by 26.84 crs Decrease in Gross Margin due to Sales Product Mix: Comfy Sales has grown by 8.36
Slide 10: Financials – YTD Dec'22 expenses
Financials – YTD Dec’22 (Rs. in Crores) Employee Benefit Expenses 36.44 35.93 YTD Dec'22 YTD Dec'21 Increase: 1.42% Advertisement & Selling Expenses Other Expenses 45.45 46.47 35.14 23.36 YTD Dec'22 YTD Dec'21 YTD Dec'22 YTD Dec'21 Decrease: 2.19% Increase: 50.43% Investor Presentation | Quarter and
Slide 11: YTD Dec'22 – OTC Division
Financials – YTD Dec’22 – OTC Division (Rs. in Crores) Gross Sales - OTC Notes: 288.33 307.79 • Key raw material prices (excluding Menthol crystal price) are higher when compared to YTD Dec’21. YTD Dec'22 YTD Dec'21 • The prices of packing materials are higher when compared to YTD Dec’21. The prices
Slide 12: YTD Dec'22 – Beverage Division
Financials – YTD Dec’22 – Beverage Division (Rs. in Crores) Gross Sales - Beverages 22.51 20.54 Notes: • Raw Material & Packing Material prices are higher when compared to YTD Dec'22 YTD Dec'21 YTD Dec’21. • Advertisement spend is at Rs. 4.39 Gross Sales - Electro Plus cr for YTD Dec’22 against Rs.
Slide 13: Q3 FY23 Performance
Q3 FY23 Performance Investor Presentation | Quarter and Period Ended 31st December 2022 12
Slide 14: Financials – Q3 FY23
Financials – Q3 FY23 (Rs. in Crores) Gross Sales Profit Before Tax Profit After Tax 122.99 27.92 20.58 108.36 14.50 10.71 Q3 FY23 Q3 FY22 Q3 FY23 Q3 FY22 Q3 FY23 Q3 FY22 Investor Presentation | Quarter and Period Ended 31st December 2022 13
Slide 15: Financials – Q3 FY23 by division
Financials – Q3 FY23 (Rs. in Crores) Gross Sales - OTC Gross Sales - Beverages 118.18 4.15 4.35 103.73 Q3 FY23 Q3 FY22 Q3 FY23 Q3 FY22 Gross Sales - Comfy Gross Sales - Electro Plus 18.06 18.15 3.71 3.40 Q3 FY23 Q3 FY22 Q3 FY23 Q3 FY22 Investor Presentation | Quarter and Period Ended 31st December 2
Slide 16: Way Forward
Way Forward Investor Presentation | Quarter and Period Ended 31st December 2022 15
Slide 17: Way Forward
Way Forward We remain focused on executing our key priorities: • Expand distribution • Go global • Grow E-Commerce vertical • Costs reduction Investor Presentation | Quarter and Period Ended 31st December 2022 16
Slide 18: Investor Presentation | Quarter and Period Ended 31st December 2022
Investor Presentation | Quarter and Period Ended 31st December 2022 17
Amrutanjan Health Care — Q3 FY23 Earnings Presentation on 6ix